Biogen (BIIB) Tops Q3 EPS by 63c, Raises Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.12 +3.04%
EPS Growth %: -41.5%
Financial Fact:
Income before income tax expense: 1.37B
Today's EPS Names:
CRMT, More
EPS Growth %: -41.5%
Financial Fact:
Income before income tax expense: 1.37B
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.77, $0.63 better than the analyst estimate of $4.14. Revenue for the quarter came in at $2.51 billion versus the consensus estimate of $2.47 billion.
GUIDANCE:
Biogen sees FY2022 EPS of $16.50-$17.15, versus the consensus of $16.49. Biogen sees FY2022 revenue of $10-10.15 billion, versus the consensus of $10.01 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen expects $164M R&D charge to hit Q2 2026 earnings
- Rivian raises 2026 delivery outlook after Q2 results top guidance
- Franklin Covey (FC) Misses Q3 EPS by 2c, lowers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
